<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462304</url>
  </required_header>
  <id_info>
    <org_study_id>END-DME1</org_study_id>
    <nct_id>NCT02462304</nct_id>
  </id_info>
  <brief_title>To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema</brief_title>
  <acronym>END-DME</acronym>
  <official_title>To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nagoya City University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asahikawa Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Fukui</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eguchi Eye Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyoto University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nagasaki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Osaka Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyushu University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tokyo Medical University Hachioji Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hokkaido University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyorin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Cheon Hyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yeungnam University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yamagata University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

      To compare the efficacy of monotherapy with anti-Vascular Endothelial Growth Factor
      (ranibizumab or bevacizumab) with combined therapy with anti-Vascular Endothelial Growth
      Factor and end-point-management grid laser photocoagulation for diabetic macular edema.

      Study design:

      Open-label non-randomized interventional study.

      Study overview:

      This study aims to look at the efficacy of treating diabetic macular edema (DME) with either
      anti-Vascular Endothelial Growth Factor(anti-VEGF) monotherapy, compared with combination
      therapy with anti-VEGF and End-Point-Management (EPM) grid laser photocoagulation, over a
      period of 6 months.

      Various sites from across Asia (Japan, South Korea, Hong Kong) will participate. Depending on
      the availability of EPM laser, sites can either contribute to the 'Anti-VEGF monotherapy'
      arm, or to the 'Combination therapy' arm.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in number of anti-VEGF required</measure>
    <time_frame>6 months</time_frame>
    <description>The number of injections of anti-VEGF required at the end of the 6 months period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>The change in best corrected visual acuity among subjects in different groups at the end of the 6 months period when compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>6 months</time_frame>
    <description>The change in central retinal thickness among subjects in different groups at the end of the 6 months period when compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related complications</measure>
    <time_frame>6 months</time_frame>
    <description>This will look at treatment related complications in terms of changes in intraocular pressure post-injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related complications</measure>
    <time_frame>6 months</time_frame>
    <description>This will look at treatment related complications in terms of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related complications</measure>
    <time_frame>6 months</time_frame>
    <description>This will look at treatment related complications in terms of retinal detachment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of macular edema</measure>
    <time_frame>6 months</time_frame>
    <description>Recurrence of macular edema during the 6 months period will be monitored.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Macula Edema</condition>
  <arm_group>
    <arm_group_label>Combination Anti-VEGF and EPM laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive both anti-VEGF injections and EPM laser.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-VEGF monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive anti-VEGF injections monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>End-Point-Management grid laser</intervention_name>
    <arm_group_label>Combination Anti-VEGF and EPM laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <arm_group_label>Combination Anti-VEGF and EPM laser</arm_group_label>
    <arm_group_label>Anti-VEGF monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Combination Anti-VEGF and EPM laser</arm_group_label>
    <arm_group_label>Anti-VEGF monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years with CSME

          -  Diagnosis of diabetes mellitus (type 1 or type 2)

          -  At least one eye meets the study eye criteria

          -  Able and willing to provide informed consent prior to any study-related procedures

          -  Central foveal thickness ≥ 300 microns at baseline (SPECTRALIS or Cirrus HD OCT)

          -  LogMAR Best corrected visual acuity 0.20 (Snellen 20/30) to 1.3 (Snellen 20/400).

          -  Willing and able to comply with clinic visits and study-related procedures

          -  Central Foveal Thickness on OCT 300-600 micron

          -  After first injection, wait for ME to reduce before proceeding with the laser. Exclude
             if ME persists &gt;500um at the 4-week follow up

        Exclusion Criteria:

          -  Macular edema is considered to be due to a cause other than diabetic macular edema.

          -  An ocular condition is present such that, in the opinion of the investigator, visual
             acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy,
             VMT, pigment epithelium abnormalities, dense subfoveal hard exudates, non-retinal
             condition such as glaucoma etc).

          -  Substantial cataract that, in the opinion of the investigator, is likely to be
             affecting visual acuity. Likely to be affecting BCVA and performing laser treatment.

          -  History of treatment for diabetic macular edema at any time in the past (such as grid
             macular photocoagulation).

          -  History of treatment for diabetic macular edema at any time in the past 3 months (such
             as intravitreal or peribulbar corticosteroids, ranibizumab, bevacizumab, aflibercept).

          -  Focal laser photocoagulation should be performed before enrolling into the study if
             needed. 3 months gap required between last laser procedure and recruitment.

          -  History of panretinal (scatter) photocoagulation (PRP) within 3 months prior to
             enrollment.

          -  Anticipated need for PRP in the study period.

          -  History of major retinal surgery (including vitrectomy, scleral buckle, any glaucoma
             surgery, etc.).

          -  History of YAG capsulotomy performed within 3 months.

          -  Aphakia.

          -  Intraocular pressure ≥ 25 mmHg.

          -  History of open-angle glaucoma (either primary open-angle glaucoma or other cause of
             open-angle glaucoma; note: history of angle-closure glaucoma is not an exclusion
             criterion).

          -  Exam evidence of external ocular infection, including conjunctivitis, chalazion, or
             significant Blepharitis.

          -  Systemic Exclusion Criteria: A subject is not eligible if any of the following
             exclusion criteria are present:

          -  Significant renal disease, defined as a history of chronic renal failure requiring
             dialysis or kidney transplant.

          -  A condition that, in the opinion of the investigator, would preclude participation in
             the study (e.g., unstable medical status including blood pressure, cardiovascular
             disease, and glycemic control).

          -  Blood pressure &gt; 180/110 (systolic above 180 OR diastolic above 110).

          -  Major surgery within 28 days prior to randomization or major surgery planned during
             the next 6 months.

          -  Myocardial infarction, other cardiac event requiring hospitalization, stroke,
             transient ischemic attack, or treatment for acute congestive heart failure within 6
             months prior to randomization.

          -  Systemic anti-vascular growth factor (ranibizumab) or pro-VEGF treatment within 4
             months.

          -  For women of childbearing potential: pregnant or lactating or intending to become
             pregnant within the next 12 months.

          -  Subject is expecting to move out of the area of the clinical center to an area not
             covered by another clinical center during the study.

          -  The target eye is the only eye of the subject, with the fellow eye's visual acuity
             lower than 1.3 LogMAR units.

          -  Baseline logMAR BCVA from 0.05 to 0.5 (Snellen)

          -  Fellow eye BCVA 0.05 or worse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Wong, FRCOphth</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>April 17, 2016</last_update_submitted>
  <last_update_submitted_qc>April 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. WONG Yat-hin Ian</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetic Macula Edema</keyword>
  <keyword>End-Point-Management</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

